Momokazu Gotoh Selected Research

silodosin

4/2021	Effects of tadalafil versus silodosin on voiding function in male patients with non-neurogenic detrusor underactivity: A comparative study using propensity score matching.
1/2020	Factors contributing to the efficacy of two add-on therapies of fesoterodine or mirabegron to silodosin monotherapy for persistent overactive bladder in men with lower urinary tract symptoms.
1/2019	Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
9/2018	Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: a prospective investigation using urodynamics.
10/2017	Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
1/2017	Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms.
1/2017	Intraprostatic Reflux of Urine Induces Inflammation in a Rat.
1/2017	Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
2/2016	The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia.
3/2013	What are the factors contributing to failure in improvement of subjective symptoms following silodosin administration in patients with benign prostatic hyperplasia? Investigation using a pressure-flow study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Momokazu Gotoh Research Topics

Disease

34	Overactive Urinary Bladder (Overactive Bladder) 01/2022 - 01/2005
32	Neoplasms (Cancer) 01/2022 - 05/2002
20	Lower Urinary Tract Symptoms 01/2022 - 12/2009
19	Prostatic Neoplasms (Prostate Cancer) 02/2022 - 04/2003
16	Stress Urinary Incontinence 07/2022 - 06/2006
15	Urinary Incontinence 04/2021 - 11/2002
15	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 05/2019 - 02/2003
13	Renal Cell Carcinoma (Grawitz Tumor) 05/2019 - 12/2003
11	Urinary Bladder Neck Obstruction (Bladder Neck Obstruction) 12/2020 - 01/2013
8	Pain (Aches) 01/2022 - 01/2013
6	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2020 - 05/2014
6	Hemorrhage 11/2017 - 08/2004
5	Cystitis 01/2017 - 04/2014
4	Neoplasm Metastasis (Metastasis) 02/2021 - 07/2008
4	Carcinoma (Carcinomatosis) 01/2021 - 04/2009
4	Urinary Bladder Neoplasms (Bladder Cancer) 12/2019 - 04/2009
4	Nocturia 01/2019 - 09/2007
4	Inflammation (Inflammations) 01/2017 - 04/2014
4	Neural Tube Defects (Exencephaly) 02/2007 - 07/2003
3	Underactive Urinary Bladder 04/2021 - 07/2010
3	Margins of Excision 01/2019 - 05/2014
2	Body Weight (Weight, Body) 07/2022 - 11/2016
2	Pelvic Pain 01/2022 - 01/2020
2	Prostatitis 01/2022 - 01/2020
2	Constipation 12/2020 - 09/2007
2	Hypertrophy 08/2020 - 09/2009
2	Disease Progression 11/2019 - 01/2012
2	Solitary Kidney 05/2019 - 06/2011
2	Hypersensitivity (Allergy) 01/2019 - 01/2017
2	Seminoma 01/2018 - 07/2008
2	Carcinogenesis 01/2018 - 11/2010
2	Urinary Retention 09/2017 - 10/2009
2	Intraoperative Complications 01/2017 - 09/2009
2	Interstitial Cystitis (Interstitial Cystitis, Chronic) 01/2017 - 01/2016
2	Lymphatic Metastasis 05/2014 - 10/2012
2	Thrombosis (Thrombus) 04/2014 - 01/2012
2	Ischemia 11/2012 - 11/2010
2	Acute Kidney Injury (Acute Renal Failure) 10/2012 - 01/2008
2	Hyperplasia 09/2011 - 04/2011
2	Angle-Closure Glaucoma (Glaucoma, Angle Closure) 07/2007 - 01/2005
2	Glaucoma 07/2007 - 01/2005

Drug/Important Bio-Agent (IBA)

12	silodosin FDA Link 04/2021 - 12/2009
11	Cholinergic Antagonists (Anticholinergics)IBA 10/2017 - 01/2005
9	Prostate-Specific Antigen (Semenogelase)IBA 05/2020 - 02/2003
7	mirabegronIBA 08/2020 - 06/2014
6	Therapeutic UsesIBA 12/2020 - 10/2012
6	naftopidilIBA 01/2019 - 09/2005
6	Tamsulosin (Flomax)FDA LinkGeneric 10/2013 - 09/2005
5	Tadalafil (Cialis)FDA Link 04/2021 - 01/2018
5	propiverineIBA 01/2018 - 09/2007
5	Solifenacin Succinate FDA Link 10/2015 - 09/2007
4	Docetaxel (Taxotere)FDA Link 02/2021 - 06/2018
4	AndrogensIBA 02/2021 - 04/2014
4	N- (4- ((5- (hydroxy(phenyl)methyl)pyrrolidin- 2- yl)methyl)phenyl)- 4- oxo- 4,6,7,8- tetrahydropyrrolo(1,2- a)pyrimidine- 6- carboxamideIBA 01/2021 - 01/2018
4	Immune Checkpoint InhibitorsIBA 01/2021 - 03/2018
4	Androgen Receptors (Androgen Receptor)IBA 11/2020 - 04/2014
4	Messenger RNA (mRNA)IBA 01/2018 - 07/2014
4	Folic Acid (Vitamin M)FDA LinkGeneric 02/2007 - 07/2003
3	Testosterone (Sustanon)FDA Link 01/2022 - 02/2016
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 04/2014
3	Dutasteride (Avodart)FDA Link 10/2017 - 08/2014
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 03/2021 - 01/2021
2	TAS-303IBA 03/2021 - 01/2021
2	salicylhydroxamic acid (SHAM)IBA 08/2020 - 01/2017
2	fesoterodine FDA Link 01/2020 - 01/2019
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 03/2017
2	Vincristine (Oncovin)FDA LinkGeneric 01/2019 - 01/2018
2	Muscarinic AntagonistsIBA 01/2019 - 09/2007
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2018 - 01/2017
2	resiniferatoxinIBA 01/2018 - 01/2017
2	Pharmaceutical PreparationsIBA 09/2017 - 04/2014
2	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2017 - 09/2005
2	Proteins (Proteins, Gene)FDA Link 01/2017 - 03/2015
2	Tyrosine Kinase InhibitorsIBA 10/2016 - 03/2014
2	Axitinib (AG 013736)IBA 10/2016 - 04/2014
2	Sorafenib (BAY 43-9006)FDA Link 04/2015 - 01/2012
2	Hematoxylin (Haematoxylon)IBA 03/2015 - 04/2014
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2015 - 04/2014
2	Eosine Yellowish-(YS) (Eosin)IBA 03/2015 - 04/2014
2	rebamipideIBA 12/2014 - 04/2014
2	Type A Botulinum Toxins (Botox)FDA Link 05/2013 - 06/2011

Therapy/Procedure

27	Therapeutics 07/2022 - 07/2011
19	Prostatectomy (Retropubic Prostatectomy) 07/2022 - 04/2003
14	Nephrectomy 01/2018 - 12/2003
7	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021 - 01/2010
6	Nephroureterectomy 01/2021 - 03/2003
6	Castration 11/2020 - 03/2017
6	Drug Therapy (Chemotherapy) 01/2019 - 04/2014
4	Aftercare (After-Treatment) 01/2022 - 01/2018
4	Operative Time 04/2009 - 05/2002
3	Suburethral Slings (Tension-Free Vaginal Tape) 01/2021 - 06/2006
3	Radiotherapy 01/2018 - 11/2017
3	Catheters 09/2017 - 11/2002
3	Lasers (Laser) 01/2017 - 01/2005
2	Lipectomy (Liposuction) 01/2021 - 03/2019
2	Blood Transfusion (Blood Transfusions) 11/2020 - 05/2002
2	Adjuvant Chemotherapy 12/2019 - 10/2012
2	Lymph Node Excision (Lymph Node Dissection) 11/2017 - 01/2017
2	Ligation 05/2011 - 04/2009
2	Sutures (Suture) 05/2011 - 08/2004